

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: J-Lat Full Length Cells (10.6)

Catalog Number: 9849

Lot Number: 140388

Release Category: С

Provided: 1 ml $(4.8 \times 10^6 \text{ cells/vial})$, viability is 89%.

Cell Type: Jurkat - T lymphocyte cell line

Propagation Medium:

RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin

(100 μ g/ml), L-glutamine (2 mM, 0.3 mg/ml).

Freeze Medium: FBS, 90%; DMSO, 10%.

Growth

Characteristics:

No special requirements, split 1:3 at 1x10⁶ cells/ml. Cells grow in suspension, usually

singly but some clumping has been noted.

Small, spherical cells in suspension. Morphology usually does not vary. Morphology:

Sterility: Negative for bacteria, mycoplasma, and fungi.

Description: This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that

expresses GFP upon activation. The genome generates incomplete virions due to a

frameshift in env.

Special Characteristics:

Jurkat cells were infected with the packaged retroviral construct HIV-R7/E-/GFP, which

is full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in

place of the Nef gene.

Full-length constructs secrete incomplete viral particles (capsids). The cells express low to undetectable levels of GFP under basal conditions. Suited to study HIV latency and

reactivation.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/13/2017 Page 1 of 2 The clones in this series are: 6.3 (cat# 9846), 8.4 (cat# 9847), 9.2 (cat# 9848), 10.6 (cat# 9849), and 15.4 (cat# 9850).

Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF-a

Recommended Storage:

Liquid nitrogen

Contributor: Dr. Eric Verdin.

Jordan, A., Bisgrove, D., & Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-1877. References:

doi:10.1093/emboj/cdg188 PUBMED

NOTE: Acknowledgment for publications should read "The following reagent was obtained

through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length Cells (clone #) from Dr. Eric Verdin." Also include the reference cited above in any

These cells and methods of use are covered by US Patents 7,232,685 and

7,544,467.

Scientists at for-profit institutions or who intend commercial use of this

reagent must contact the J. David Gladstone Institutes, Email:

veronica.viray@gladstone.ucsf.edu, before the reagent can be released. Please

specify the name and a description of the intended use of the reagent.

Last Updated December 13, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/13/2017 Page 2 of 2